GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Hemostemix Inc (OTCPK:HMTXF) » Definitions » Policy Acquisition Expense

HMTXF (Hemostemix) Policy Acquisition Expense


View and export this data going back to 2015. Start your Free Trial

What is Hemostemix Policy Acquisition Expense?

Policy Acquisition Expense only applies to insurance companies.


Hemostemix Business Description

Traded in Other Exchanges
Address
707 - 7th Avenue SouthWest, Suite 1150, Calgary, AB, CAN, T2P 3H6
Hemostemix Inc is a biotechnology company. The company's principal business activity is developing, manufacturing, and commercializing blood-derived cell therapies for medical conditions. The Company's technology is a platform for developing autologous cell therapies to treat vascular diseases. The Company's clinical stage consists of ACP-01, autologous cell therapy for the treatment of critical limb ischemia.